Arrowstreet Capital Limited Partnership Grows Position in STERIS plc $STE

Arrowstreet Capital Limited Partnership increased its position in STERIS plc (NYSE:STE) by 666.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 221,039 shares of the medical equipment provider’s stock after buying an additional 192,208 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.22% of STERIS worth $53,098,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP grew its holdings in STERIS by 7.3% in the 2nd quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 45 shares during the last quarter. Ashton Thomas Private Wealth LLC raised its stake in shares of STERIS by 3.5% during the first quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock valued at $365,000 after acquiring an additional 54 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of STERIS by 0.9% during the first quarter. Cetera Investment Advisers now owns 6,999 shares of the medical equipment provider’s stock worth $1,586,000 after purchasing an additional 63 shares during the period. Horizon Investments LLC boosted its holdings in shares of STERIS by 4.7% during the first quarter. Horizon Investments LLC now owns 1,410 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 63 shares during the period. Finally, Berry Wealth Group LP grew its stake in shares of STERIS by 5.3% in the second quarter. Berry Wealth Group LP now owns 1,251 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 63 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Trading Up 0.6%

Shares of NYSE STE opened at $260.93 on Friday. STERIS plc has a 1 year low of $200.98 and a 1 year high of $268.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. The firm has a 50-day moving average of $249.71 and a 200 day moving average of $243.39. The stock has a market cap of $25.61 billion, a P/E ratio of 37.49 and a beta of 1.01.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the company earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, sell-side analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s payout ratio is presently 36.21%.

Analyst Upgrades and Downgrades

STE has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Finally, Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

Insider Buying and Selling

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total value of $3,977,100.00. Following the transaction, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,203 shares of company stock valued at $6,624,667. 1.07% of the stock is owned by insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.